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Abstract
 
T cell epitope peptides derived from proteolipid protein (PLP139–151) or myelin basic protein
(MBP86–100) induce experimental autoimmune encephalomyelitis (EAE) in “susceptible”
strains of mice (e.g., SJL/J). In this study, we show that the encephalitogenic effect of these
epitopes when injected subcutaneously in complete Freund’s adjuvant was significantly en-
hanced if administered to the animal in a multimerized form as a T cell epitope oligomer (i.e.,
as multiple repeats of the peptide epitope, such as 16-mers). Oligomer-treated SJL/J mice de-
veloped EAE faster and showed a more severe progression of the disease than animals treated
with peptide alone. In addition, haplotype-matched B10.S mice, “resistant” to EAE induction
by peptide, on injection of 16-mers developed a severe form of EAE. Even more striking,
however, was the dramatic suppression of incidence and severity of the disease, seen after single
 
intravenous injections of only 50 
 
m
 
g of the PLP139–151 16-mer, administered to SJL/J mice
7 d after the induction of the disease. Although relapse occurred at about day 45, an additional
injection several days before that maintained the suppression. Importantly, the specific suppres-
sive effect of oligomer treatment was also evident if EAE was induced with spinal cord homog-
enate instead of the single peptide antigen. By contrast, the PLP139–151 peptide accelerated
rather than retarded the progression of disease.
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Introduction
 
T cell epitope oligomers are linear polypeptide chains,
which consist of multiple copies of a T cell epitope. They
contain up to 32 repeats of the epitope connected to each
 
other by a flexible spacer sequence (sp)
 
1
 
 of 
 
z
 
13 amino ac-
ids. Previously, oligomers (16-mers) of an epitope derived
from the influenza virus hemagglutinin protein (HA306–
318) have been shown to induce an exceptionally strong
 
CD4
 
1
 
 T cell proliferative response in vitro (at almost
1,000-fold lower concentration than the peptide) (1). To
evaluate whether oligomers can also act as stronger immu-
nogens in vivo, experimental animal models were needed.
Experimental autoimmune encephalitis (EAE) is the best
studied experimental animal model of a T cell–mediated
autoimmune disease. It serves as the animal model of hu-
man multiple sclerosis (2) and can be initiated by a subcuta-
neous injection of encephalitogenic peptides. In most cases,
these peptides are “self-antigens” deriving from myelin
proteins (3), such as proteolipid protein (PLP [4, 5]), my-
elin basic protein (MBP [6, 7]), or myelin oligodendrocyte
protein (MOG [8]). These peptides, when associated to
MHC class II molecules, are the target structure for autore-
active CD4
 
1
 
 T cells.
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lar and Cellular Biology, Harvard University, 7 Divinity Ave., Cam-
bridge, MA 02138. Phone: 617-495-2733; Fax: 617-496-8351; E-mail:
jlstrom@fas.harvard.edu
 
1
 
Abbreviations used in this paper:
 
 EAE, experimental autoimmune en-
cephalomyelitis; HA, influenza hemagglutinin protein; LNC, lymph node
cell; MBP, myelin basic protein; MOG, myelin oligodendrocyte protein;
PLP, proteolipid protein; sp, spacer sequence. 
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The extent of the pathological changes after the induc-
tion of the disease can be evaluated by scoring the clinical
symptoms typical for EAE. This clinical score reflects the
“encephalitogenicity” of the antigen and can be used to es-
timate its in vivo
 
 
 
potency. However, not all mouse strains
respond equally to a given encephalitogenic peptide anti-
gen. Incidence rate and severity of the disease are strongly
affected by the genotype of the recipient mouse. Primarily,
the H2 haplotype dictates whether the strain is “permis-
sive” or “nonpermissive” for disease induction by the par-
ticular antigen, but in addition other genetic factors play a
role ultimately determining whether a permissive strain is
actually also “susceptible” (9). The secondary mechanisms
underlying “susceptibility” and “resistance” are not known
at the present time, but they appear to affect the overall
sensitivity for the induction of an immune response. As a
consequence, the induction of EAE in resistant strains, such
as B10.S, requires the coinjection of proinflammatory cy-
tokines such as IL-12 (10) or might require exceptionally
strong immunogens.
The use of the EAE system for the evaluation of the in
vivo potency also allows testing the potential of an antigen
to suppress the immune response. In addition to therapeu-
tic approaches using broadly immunosuppressing mecha-
nisms such as the administration of antiinflammatory cy-
tokines (11) or the neutralization of proinflammatory
cytokines (12), other more targeted approaches were intro-
duced to “silence” specifically the autoreactive T cells.
Most of these approaches aim at the induction of “high
zone tolerance” (13), i.e., the induction of anergy (14) or
the apoptotic elimination (15) of T cells by overstimulation
after exposure to high concentrations of antigen. To
achieve tolerance, the antigens have to be administered ei-
ther by oral uptake (16–18), by intranasal deposition (19),
or by intravenous or subcutaneous injection (14, 15, 20,
21). Using these routes of administration, several antigens
have already been used successfully in the EAE system to
induce tolerance. The list includes peptides (14, 15, 20) or
peptide derivates modified by acylation (22) or amino acid
substitution (23), but also proteins (21, 24) and protein–
protein (25) and immunoglobulin–protein chimeras (26).
However, these experiments were usually carried out in
transgenic animals, which express only the TCR specific
for the peptide antigen (15, 20). Few reports exist in which
“normal” nontransgenic mice were treated successfully
with encephalitogenic self-peptides after the disease was al-
ready induced (27). In these cases, however, a relatively
high internal level of the antigen had to be maintained by
the frequent administration of high doses of the peptide.
In this study, we tested the efficiency of multimerized
forms of the encephalitogenic T cell epitopes PLP139–151
(4) and MBP86–100 (7) on both the induction and sup-
pression of EAE. The disease induction was tested with
several mouse strains, including resistant B10.S mice in
which the peptides were known to have no encephalito-
genic effect. The effect on the suppression of the autoim-
mune disease was tested with normal SJL/J mice, not bi-
ased by the transgenic expression of a particular TCR.
 
Materials and Methods
 
Antigens.
 
For stability reasons, the residue Cys140 in the
PLP139–151 epitope was substituted by Ser (a substitution that
has no or little effect on the encephalitogenicty of the epitope
[4]). The synthetic peptides PLP139–151(C140S) (HSLGKWLG-
HPDKF), PLP139–151 (HCLGKWLGHPDKF), sp-PLP139–151
(C140S)-sp (GGGPGGHSLGKWLGHPDKFGGPGGG), PLP178–
191(C183S) (NTWTTSQSIAFPSK), MBP86–100 (NPVVHFF-
KNIVTPRT), and MBP86–101 (NPVVHFFKNIVTPRTP) were
produced by using standard solid phase F-moc chemistry and
purchased from the Biopolymers Laboratory at the Harvard Med-
ical School. All peptides were purified on a C
 
4
 
-HPLC column
(Vydac).
Oligomerized T cell epitopes were produced in 
 
Escherichia coli
 
bacteria using recombinant techniques as described previously
(1). In brief, double-stranded oligonucleotide units encoding
the T cell epitopes of the PLP139–151(C140S) oligomers and
MBP86–100 oligomers were generated by annealing two com-
plementary strands of synthetic oligonucleotides (PLP139–151
(C140S), 
 
1
 
 strand: 5
 
9
 
-TCACTCTCTGGGTAAATGGCTGGG-
TCACCCGGATAAATTCGG, and 
 
2
 
 strand: 5
 
9
 
-GAATTT-
ATCCGGGTGACCCAGCCATTTACCCAGAGAGTGACC;
MBP86–100, 
 
1
 
 strand: 5
 
9
 
-CAACCCGGTTGTTCACTTCT-
TCAAAAACATCGTAACTCCGCGTACTGG, and 
 
2
 
 strand:
5
 
9
 
-AGTACGCGGAGTTACGATGTTTTTGAAGAAGTGAA-
CAAGCGGGTTGCC). They were linked to the NH
 
2
 
-terminal
side of a spacer sequence (amino acid sequence of the S3 spacer:
GGPGGGPGGGPGG) by cloning the oligonucleotides into the
BsrDI site of a modified pCITE vector (Novagen), which con-
tained the DNA encoding the S3 spacer (the construction of full-
length oligomeric DNA is described in reference 1). The same
spacer was also used in MBP86–101 oligomers, which were pro-
vided by Dr. Shan Chung (Peptimmune, Inc., Cambridge, MA).
The proteins were produced in TOP10 (pLysS) bacteria (Invitro-
gen) by using a pET22b expression vector (Novagen). The puri-
fication of the expressed protein was carried out using Ni
 
2
 
1
 
-
NTA-agarose (Qiagen) by using a His tag located at the COOH
terminus of the constructs. Endotoxin and other impurities were
removed from the polypeptide oligomers by separation on a re-
versed-phase C
 
4
 
-HPLC column (Vydac).
Spinal cords from mice were isolated, homogenized, and ly-
ophilized as described elsewhere (28).
 
T Cell Lines and Clones.
 
The T cell lines SP/2, SP/3, PLP/a,
and PLP/c were generated and maintained as described previ-
ously (29). In brief, SJL mice were immunized subcutaneously
with PLP139–151(C140S) peptide emulsified in CFA. Lymph
node cells (LNCs) were isolated on day 8–12 after immunization
and initially stimulated with 50 
 
m
 
g/ml PLP139–151(C140S) in
the presence of 0.8–1.0% autologous mouse serum. The cultures
were subsequently restimulated after 6 d and then every 2–3 wk
with 10 
 
m
 
g/ml PLP139–151(C140S) and irradiated syngeneic
splenocytes (1,200 rad). They were expanded in DMEM (supple-
mented with 20 mM glutamine, 1 mM sodium pyruvate, 0.1
mM nonessential amino acids, 10 mM Hepes buffer, 10% FCS
[Sigma Chemical Co.]) plus 5–10% of a supernatant derived from
concanavalin A–activated mouse splenocytes. The T cell line SP/
178 was generated in the same way except that PLP178–191 was
used instead of PLP139–151(C140S). The T cell clones SP2.2A8
and 8A1 were obtained by limiting dilution of T cell lines specific
for the PLP139–151 antigen at a density of 0.5 cells/well and
maintained as described for the T cell line. T cell hybridomas
hPLP/1, hPLP/a9.4, and hPLP/c4 were generated by a polyeth-
ylene glycol fusion of the T cell lines PLP/a and PLP/c, respec- 
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tively, with TCR-
 
a
 
/
 
b
 
2
 
 BW1100 thymoma cells, selected in the
presence of histone acetyltransferase (HAT) and cloned by limit-
ing dilution as described previously (29).
 
Mice.
 
SJL/J, PL/J, SWR, B10.S, B10, BALB/c, A.SW, and
AKR/J mice (6–8 wk of age) were purchased from The Jackson
Laboratory and housed in the animal facility at Harvard Univer-
sity or at Harvard Medical School. They were maintained in ac-
cordance with the Guidelines of the Committees on Animals of
Harvard University, and the Committee on Care and Use of
Laboratory Animal Resources, National Research Council (De-
partment of Health and Human Services Publication 85–23, re-
vised 1987).
 
In Vitro Assays.
 
T cell proliferation assays were performed in
96-well round-bottomed plates using 5 
 
3
 
 10
 
5
 
 irradiated (1,200
rad) splenocytes and 5 
 
3
 
 10
 
4
 
 T cells per well in DMEM/10%
FCS. After 48 h, 5 
 
m
 
Ci [
 
3
 
H]thymidine was added per well and
the assay was harvested after 72 h and counted in a microbeta-
plate reader (Wallac). The in vitro proliferation assays of primary
LNC cultures were performed in the same way except that 5 
 
3
 
10
 
5
 
 nonirradiated LNCs were plated per well, [
 
3
 
H]thymidine was
added after 72 h, and the assay was harvested after 96 h. The re-
sponse of T cell hybridomas (5 
 
3
 
 10
 
5
 
 cells/well) was tested with
5 
 
3
 
 10
 
5
 
 splenocytes as target cells by collecting 30 
 
m
 
l of superna-
tant after 24 h for the determination of IL-2 release in a prolifera-
tion assay with CTLL.
 
Induction of EAE.
 
Mice were injected in the base of the tail
and the nape of the neck with indicated amounts of peptide, T
cell epitope oligomer, or spinal cord homogenate together with
400 
 
m
 
g 
 
Mycobacterium tuberculosis
 
 H37Ra (Difco Laboratories) in
an emulsion consisting of equal parts of PBS and CFA (Sigma
Chemical Co.). Each mouse was also injected intravenously with
200 ng of 
 
Pertussis
 
 toxin (List Biological Laboratories) on day 1 or
on days 1 and 3 after immunization. Mice were observed once or
twice a day for clinical signs of EAE and scored on a scale of 1–5
according to the severity of the clinical signs as described previ-
ously (28).
 
Suppression of EAE by Intravenous Injections.
 
EAE was induced
in SJL/J mice by the subcutaneous application of peptide antigens
or homogenized mouse spinal cord emulsified in CFA followed
by the injection of 
 
Pertussis
 
 toxin as described above. For the in-
travenous administration, the antigens were dissolved in PBS at a
concentration of 0.5–1.0 mg/ml and injected into the tail vein at
the dosage and time (day) indicated in the text.
 
Cytokine Detection.
 
Samples of the supernatant from primary
LNC cultures described above were taken after 96 h. The
amount of released IL-4 and IFN-
 
g
 
 was determined in a sand-
wich ELISA using pairs of specific capture and biotinylated de-
tection antibodies (PharMingen) and streptavidin–horseradish
peroxidase (Sigma Chemical Co.). The ELISA was developed
with TMB (Kirkegaard & Perry Laboratories) and measured at
450 nm using an MRX ELISA reader (Dynatech). IL-2, released
by T cell hybridomas, was determined by collecting 30-
 
m
 
l sam-
ples of the supernatant 24 h after commencement of the T cell as-
say by testing the samples in a secondary proliferation assay with
IL-2–dependent CTLL cells. Recombinant mIL-2 (Genzyme)
was used as reference.
 
Immunohistochemistry.
 
For assessment of inflammation, the
brain and spinal cord were fixed in formalin, embedded in paraf-
fin, and 7-
 
m
 
m sections were stained with hematoxylin and eosin
according to standard pathological procedures. For assessment of
demyelination, animals were perfused under anesthesia through
the ascending aorta with 40 ml of Trump’s fixative (4% paraform-
aldehyde, 1% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4).
 
Slices of the brain and spinal cord were postfixed in cold 1% os-
mium tetroxide for 1 h, dehydrated through a graded series of
ethyl alcohol, and embedded in epoxy resin. 1-
 
m
 
m sections were
stained with toluidine blue and examined by light microscopy in
a blinded fashion.
 
Results
 
Proliferative Response of PLP139–151-specific T Cells In
Vitro.
 
In a series of proliferation assays, the biological ac-
tivity of a PLP139–151(C140S) 16-mer was tested with
several different T cell lines and clones (generated as de-
scribed in Materials and Methods; Fig. 1 A). Compared
with the peptide, all T cell lines specific for the PLP139–
151 epitope responded better (lines SP/2, SP/3), or at least
equally well, to the stimulation with the oligomer (lines
PLP/a, PLP/c). No proliferation was induced by the
PLP139–151(C140S) 16-mer in the control line, SP/178,
which is specific for PLP178–191. As had been established
previously for another epitope (HA306–318; reference 1),
the gain in sensitivity detected for some of these lines was
significant. The T cell line SP2, for example, required
 
z
 
100-fold lower concentrations of the 16-mer to induce a
proliferation equivalent to that of the peptide. A more de-
tailed picture of the proliferative response to the PLP139–
151(C140S) 16-mer and peptide was obtained by analyzing
single T cell clones. In particular, the response of low-avid-
ity T cell clones improved to the 16-mer. As shown, some
of these clones recognized 100-fold less 16-mer than pep-
tide similar to the SP/2 line (SP2/2A8, hPLP/1), and for
some clones (e.g., hPLP/a9.4) the specificity for 16-mer
appeared even almost absolute. In contrast, other T cell
clones (e.g., hPLP/c4) failed to efficiently recognize the
16-mer. For these clones, however, the failure to respond
to the oligomer was found to be due to the extension of
the actual T cell epitope by the spacer sequence, which
presumably caused steric hindrance of the TCR–MHC–
antigen interaction (data not shown).
In the HA306–318 system, it has been shown that both
the spacer length and the length of the oligomer (i.e., num-
ber of repetitive epitope units) have a profound effect on
the outcome of the T cell response. Testing the SP/2 line
with a set of PLP oligomers revealed that also in the PLP
system the oligomer length had a similar effect (Fig. 1 B,
left). The strongest response was triggered with a 16-mer,
whereas the 4-mer, the shortest oligomer tested in this ex-
periment, required 5–10 times higher concentrations. Sim-
ilar results were also obtained with the T cell clone 8A1
(Fig. 1 B, right). To determine the influence of the spacer
on the T cell recognition, this clone was also tested with a
synthetic peptide, in which the actual core epitope was ex-
tended by parts of the spacer (sp-peptide-sp, see Materials
and Methods; Fig.1 B, right). Although the multimeriza-
tion of the epitope resulted in a significant increase in anti-
genicity (
 
.
 
1 log for the 4-mer and 
 
.
 
2 logs for the 16-
mer), the extension of the epitope by the spacer sequence
caused only a slight improvement in the proliferative re-
sponse. The influence of oligomer length was not evident 
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in lines that did not show an improved response to the
oligomers, and the trend was even reversed in clones that
recognized oligomers only weakly (e.g., hPLP/c4, data not
shown).
T cells that responded most effectively to the stimulation
with the 16-mer often showed a reduced proliferation after
exposure to the highest 16-mer concentrations (10 or 50
 
m
 
g/ml). For instance, a maximal proliferative response for
the SP/2 (Fig. 1 B, left) and SP/3 lines (Fig. 1 A, top left)
or the clone 8A1 (Fig. 1 B, right) or SP/2.2A8 (Fig. 1 A,
middle) was triggered at a concentration of 
 
z
 
0.5–1.0 
 
m
 
g/
ml 16-mer. The effect resembled high zone suppression
and was not seen after incubation with the peptide.
 
Ex Vivo Response of Primary T Cell Cultures.
 
To deter-
mine whether the improved antigenicity, observed for
some of the T cells in vitro, would translate into an in-
creased immunogenicity, mice were immunized with the
PLP139–151(C140S) peptide, with the 16-mer or, as a
control, with adjuvant only (Fig. 2). Primary cell cultures,
established from the draining LNs of the primed mice,
were then challenged in vitro with titrated amounts of the
PLP139–151(C140S) peptide or the 16-mer. PLP139–151
is restricted by I-A
 
s
 
, and mice from three different strains
were used: SJL/J, which are permissive (I-A
 
s
 
) and EAE sus-
ceptible; B10.S, which are permissive (I-A
 
s
 
) but EAE resis-
tant (30), and BALB/c, which, in principle, are EAE sus-
ceptible but are not permissive for this particular epitope
(I-A
 
d
 
).
A specific proliferative response was only observed in the
primary cultures derived from SJL/J and B10.S mice
treated with antigens (Fig. 2 A, panels 2, 3, 5, and 6). No
proliferation was detected in cultures established from
BALB/c mice (panels 7–9) and in the control cultures de-
rived from mice primed with adjuvant only (panels 1, 4,
and 7). The strength of the T cell response was more vigor-
ous in most cases if the primary culture was stimulated with
the 16-mer. This was particularly evident in cultures gener-
ated from oligomer-primed mice. Here, often 
 
,
 
100-fold
lower concentrations of 16-mer than of the peptide were
effective (panels 3 and 6). The relative enhancement was
more variable in the cultures derived from peptide-primed
mice, and frequently these cultures responded equally well
to the stimulation by peptide or 16-mer (e.g., Fig. 2 A,
panel 2). Cultures derived from mice primed with the 16-
mer usually responded strongly to the 16-mer, but in most
cases only relatively weakly to the stimulation with the
monomeric peptide. The weak response against the peptide
might be explained by the predominant stimulation by the
16-mer of low-affinity clones (as suggested by the previous
in vitro experiments), whereas the monomer is recognized
Figure 1. In vitro experiments with
PLP139–151-specific T cells. (A) T cells
raised against the PLP139–151(C140S) pep-
tide were challenged with titrated amounts
of the PLP139–151(C140S) peptide or the
PLP139–151(C140S) 16-mer. The specific
response of the T cell lines SP/3, PLP/a,
PLP/c, and SP/2, and of the T cell clone
SP/2.2A8 was measured in a proliferation
assay. The response of the T cell hybridomas
hPLP/1, hPLP/a9.4, and hPLP/c4 was de-
termined by their IL-2 release. Also shown
is the proliferative response of the line SP/
178, specific for PLP178–191. SJL/J spleno-
cytes were used as target cells. (B) Dose–
response of PLP139–151-specific T cells to
oligomers with an increasing number of re-
petitive epitope units. SP/2 T cells (left)
were tested as described above with the
PLP139–151(C140S) peptide and a set of
PLP139–151(C140S) oligomers. The right
panel shows the proliferative response of the
clone 8A1. In addition to the the PLP139–
151(C140S) peptide, the 4-mer, and the 16-
mer, this clone was also tested with a
PLP139–151(C140S) peptide containing the
NH2- and COOH-terminal extensions of
the spacer sequence (sp-peptide-sp: GGG-
PGG-PLP139–151[C140S]-GGPGGG). 
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only by high-affinity clones. In any case, in susceptible SJL
mice as well as in resistant B10.S mice, a strong and specific
T cell response could be generated by the immunization
with the oligomer (panels 3 and 6). The priming with pep-
tide, in particular in B10.S mice (panel 5), usually resulted
in weakly responding primary cultures.
No IL-4 was detectable in any of these cultures (not
shown). On the other hand, IFN-
 
g
 
 was found in the su-
pernatants of all the primary cell cultures derived from anti-
gen-primed mice, in particular after the challenge with the
16-mer. As an example, the IFN-
 
g
 
 release of the cultures
derived from B10.S mice is shown in Fig. 2 B. Although
only relatively small amounts (
 
z
 
1 ng/ml) were detected in
cultures generated from peptide-primed mice, 
 
.
 
6 ng/ml
of IFN-
 
g
 
 was measured in the supernatants derived from
cultures of 16-mer–primed mice. The relatively high levels
of IFN-
 
g
 
 might be indicative of a preferred expansion of
Th1 T cells after the immunization with the PLP 16-mer.
 
In Vivo Effect of PLP139–151(C140S) Oligomers.
 
To
determine whether the increased immunogenicity of the
oligomer also results in an enhanced encephalitogenicity, a
series of in vivo experiments was performed (Fig. 3). After
the subcutaneous immunization of SJL/J mice with titrated
amounts of either PLP139–151(C140S) peptide or the 16-
mer, the mice were observed for the appearance of the typ-
ical clinical signs of EAE (Fig. 3 A). The score of the clini-
cal symptoms revealed that SJL/J mice were more sensitive
to EAE induction with the oligomer than with peptide.
Compared with mice immunized with the peptide, they
showed an earlier onset and a much more severe progres-
sion of the disease. At a dosage of 50 
 
m
 
g, the peptide-
primed mice developed EAE on day 13 and had a maximal
clinical score of 3.75 (incidence: 3/4, mortality: 75%). In
contrast, the group primed with the 16-mer showed the
first signs of the disease almost 4 d earlier (day 9) and
reached the maximal clinical score of 5 (i.e., incidence: 4/4;
Figure 2. Ex vivo response of primary LN
cultures. (A) Proliferative response of primary
LN cultures of mice previously immunized
with 50 mg of either the PLP139–151(C140S)
peptide (panels 2, 5, and 8) or the 16-mer
(panels 3, 6, and 9). Primary LN cultures were
prepared from SJL/J mice (panels 1–3), B10.S
mice (panels 4–6), and BALB/c mice (panels
7–9). The H2 haplotype and the EAE suscep-
tibility (susc.)/resistance (resist.) of the strains
are indicated. The LNCs were isolated 7–12 d
after the immunization and challenged in vitro
by adding titrated amounts of the unsubsti-
tuted PLP139–151 peptide, the PLP139–151
(C140S) peptide, or the PLP139–151(C140S)
16-mer. As control, the response of cultures
derived from mice treated with adjuvant only
is shown (panels 1, 4, and 7). (B) Proliferative
response (top) and the cytokine release (bot-
tom) of primary LN cultures derived from
B10.S mice. The amount of IFN-g was deter-
mined in supernatants taken 96 h after the
start of the experiment. 
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mortality: 100%). The trend also continued at lower dos-
ages of the antigens. Although at the dosage of 10 
 
m
 
g al-
most no clinical signs of disease were observed in the group
primed with the peptide (incidence: 1/4; mean maximum
score: 0.25), 16-mer–primed SJL mice developed a severe
disease (incidence: 4/4; onset: day 11.5; mean maximum
score: 5; mortality: 100%). Even at the lowest dosage tested
(2 
 
m
 
g), a mild form of EAE was still evident in the group
treated with the 16-mer (incidence: 2/4; onset: day 13;
mean maximum score: 0.5;
 
 
 
mortality: 0%). At this dosage,
no effect was seen in the peptide group.
In the second part of this experiment, we addressed the
question as to whether the oligomer could also induce EAE
in resistant B10.S mice (Fig. 3 B). In accordance with pre-
vious reports (31), no clinical signs of the disease were ob-
served in the B10.S group primed with the peptide. The
16-mer, in contrast, was also encephalitogenic in this strain
(no effect with the peptide or the 16-mer was observed in
the BALB/c control group). The EAE was only slightly less
severe than in SJL/J mice and, at a dosage of 50 
 
m
 
g, in-
duced the disease with an incidence rate of 100%. Com-
pared with SJL/J mice, in B10.S mice the onset of the dis-
ease was delayed by 
 
z
 
3 d and resulted in a mean maximum
score of 3.0. CNS immunohistochemistry performed on
brain and spinal cord samples of the 16-mer–treated B10.S
mice (Fig. 4) revealed an extensive submeningeal, perivas-
cular, and parenchymal infiltration (Fig.4, panel 2), as well
as demyelination (panel 4). In contrast, only some minor
submeningeal infiltration (panel 1) and no demyelination
(panel 3) was detectable in the samples from peptide-
primed B10.S mice.
To demonstrate that induction of EAE was limited only
to permissive strains, mouse strains with various H2 haplo-
types were primed with either the peptide or the 16-mer
(Table I). In all tested I-A
 
s
 
–expressing mouse strains, the
treatment with the oligomer resulted in the induction of
EAE. A.SW, for example, showed symptoms comparable
to the ones described for SJL/J. No clinical signs of the dis-
ease were observed in mice of the b, d, k, q, and u haplo-
types.
 
In Vivo Effect of MBP86–100 Oligomers.
 
To extend the
study to other encephalitogenic T cell epitopes, oligomers
were tested in which the PLP139–151(C140S) epitope was
replaced by a T cell epitope derived from the MBP protein
Figure 3. Induction of EAE with PLP139–151(C140S) oligomer. (A) Dose–response curves of peptide and 16-mer in susceptible SJL/J mice. EAE was
induced in groups of four mice by subcutaneous injection of either 50 mg (top), 10 mg (middle), or 2 mg (bottom) of the PLP139–151(C140S) peptide or
the 16-mer. The progression of the disease was determined on a daily basis by monitoring the mice for the appearance of clinical symptoms. The severity
of the EAE is expressed in the mean score of these symptoms. Four mice per group were used. (B) EAE induction in susceptible and resistant strains. The
encephalitogenic effect of 16-mer and peptide was tested with SJL/J mice (permissive/susceptible, top), B10.S mice (permissive/resistant, middle), or
BALB/c mice (nonpermissive/susceptible, bottom). The mice were immunized subcutaneously with 50 mg of either the PLP139–151(C140S) peptide or
the 16-mer. Filled circles of the peptide-treated BALB/c group are covered by the open symbol of the 16-mer–treated group. The clinical scores repre-
sent a compilation of several experiments using the following numbers of mice: SJL/J, 10 (peptide) and 14 (16-mer); B10.S, 9 (peptide) and 11 (16-mer);
BALB/c, 6 (peptide) and 8 (16-mer). 
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(MBP86–100). In vitro experiments indicated that, at least
in the I-As system, MBP86–100 has a significantly lower
antigenicity than PLP139–151. T cells, which show an im-
proved response to the oligomer, seem to be less frequent
in SJL mice and the ex vivo experiments revealed less im-
pressive results compared with the PLP139–151 system
(data not shown). However, to test if MBP86–100 oligo-
mers showed some enhanced encephalitogenicity, the same
series of in vivo experiments was performed as described
previously for the PLP oligomers (Fig. 5).
Figure 4. Pathological analy-
sis of resistant B10.S mice after
EAE induction with PLP139–
151(C140S) oligomers. B10.S
mice were sensitized subcutane-
ously with 50 mg of either the
PLP139–151(C140S) peptide
(panels 1 and 3) or the 16-mer
(panels 2 and 4). 14 d after dis-
ease induction, the animals were
perfused with fixative. Paraffin-
embedded sections of the brain
were stained with hematoxylin
and eosin to detect inflamma-
tory infiltrates (panels 1 and 2,
original magnifications: 3350),
and plastic-embedded sections of
the lumbar spinal cord were
stained with toluidine blue to de-
tect demyelination (panels 3 and 4,
original magnifications: 3750). In
animals sensitized with PLP139–
151(C140S) peptide, no evi-
dence of inflammation was de-
tected in the brain (panel 1), and
no inflammation or demyelina-
tion was noted within the spinal
chord parenchyma (panel 3). In
contrast, in the brains of animals
sensitized with the 16-mer,
dense accumulations of perivas-
cular cells were observed around
vessels overlying the anterior thalamus (arrows, panel 2). In the spinal cord, inflammatory cells were noted around blood vessels (bv), and inflammation,
primary demyelination (arrows), and intramyelinic edema were detected within the anterior columns.
Table I. Clinical EAE in Various Strains of Mice
Mice Incidence of EAE* Percent disease‡ Percent mortality§ Maximum mean scorei Mean day of onseti
Strain
H2
haplotype Peptide 16-mer Peptide 16-mer Peptide 16-mer Peptide 16-mer Peptide 16-mer
SJL/J s 17/20 14/14 85 100 40 100 3.1 6 2.0 5.0 6 0.0 14.0 6 1.5 10.5 6 1.2
A.SW s 5/6 6/6 83 100 66 100 3.5 6 2.3 5.0 6 0.0 13.8 6 2.0 9.8 6 0.7
B10.S s 0/9 15/15 0 100 0 33 0 3.1 6 1.5 – 13.3 6 3.0
BALB/c d 0/6 0/8 0 0 0 0 0 0 – –
B10 b 0/4 0/4 0 0 0 0 0 0 – –
AKR/J k 0/4 0/4 0 0 0 0 0 0 – –
SWR q 0/4 0/4 0 0 0 0 0 0 – –
PL/J u 0/4 0/4 0 0 0 0 0 0 – –
EAE induction with PLP139–151(C140S) oligomers in different strains of mice. Mice from various strains were immunized with 50 mg of either the
PLP139–151(C140S) 16-mer or the peptide as described in Materials and Methods.
*Values represent the number of mice with clinical signs of EAE as a fraction of the total number of immunized mice.
‡Values represent the percentage of immunized mice with clinical signs of disease.
§Values representing the percentage of mortality refer to the total number of immunized mice.
iValues representing mean day of onset and maximum mean clinical grade were scored as described in reference 28.724 Induction and Suppression of EAE by Epitope Multimers
The MBP86–100 16-mer was found to be a fairly potent
inducer of EAE. Compared with the effect of the peptide,
the application of the 16-mer resulted in an earlier onset
and more severe progression of the disease. In a dose–
response study with SJL/J mice (Fig. 5, left), disease induc-
tion with the peptide was only observed after an injection
of 100 mg, the highest dosage used in this experiment (inci-
dence: 2/4, onset: 13.5, maximal mean score: 1.7, mortal-
ity: 0%). One third of this amount, 33 mg, was insufficient
to trigger EAE. In contrast, the effect of the MBP86–100
16-mer was significantly stronger. At a dosage of 100 mg,
all of the SJL mice treated with the 16-mer developed a fa-
tal disease (incidence: 4/4, onset: 10.7, maximal mean
score: 5.0, mortality: 100%). The encephalitogenic effect
decreased at 33 mg (incidence: 3/4, onset: 13.6, maximal
mean score: 2.75, mortality: 50%) but was still evident at a
dosage of 11 mg where some cases of mild forms of EAE
were observed (incidence: 2/4, onset: day 16.5, maximal
mean score: 0.75, mortality: 0%). Importantly, it was also
possible to induce EAE in B10.S mice (Fig. 5, right). Com-
pared with the PLP139–151 system, the effect of the
MBP86–100 16mer was weaker but 50 mg of the antigen
was still sufficient to induce the disease in the majority of
the tested animals (incidence: 3/5; onset: day 18; maximal
mean score: 1.6; mortality: 20%). The same treatment with
the peptide did not cause any effect.
Effect of Intravenous Administration of Oligomers on the Pro-
gression of EAE. To examine whether the oligomers
could have a potential therapeutic impact in the suppres-
sion of EAE, mice were treated by intravenous injections
Figure 5. Induction of EAE with
MBP86–100 oligomers. Clinical scores of
mice treated subcutaneously with MBP86–
100 peptide or MBP86–100 16-mer. The
experiment was carried out as described in
the legend to Fig. 3. The SJL/J and B10.S
mice received the amounts of antigens indi-
cated in the figure. Four mice per group
were used in these experiments.
Figure 6. Suppression of EAE by intra-
venous injections of PLP139–151(C140S)
oligomers. SJL/J mice were treated with in-
travenous injections of either PLP139–
151(C140S) peptide (top) or the 16-mer
(bottom) several days before (left) or after
(right) disease induction. EAE was induced
by a subcutaneous injection of 50 mg
PLP139–151(C140S) peptide emulsified in
CFA (filled arrowhead). The mice received
the intravenous injections of peptide or 16-
mer on the day indicated by small open ar-
rows. The daily mean clinical scores of the
mice treated intravenously with antigens are
shown in comparison to the score of con-
trol groups, which received mock intrave-
nous injections of PBS instead of antigen.
Groups of five or six mice were used for the experiments. The incidence rates were determined as 5/5 (control), 5/5 (peptide), and 2/5 (16-mer) for the
groups treated before the disease induction and as 6/6 (control), 6/6 (peptide), and 4/6 (16-mer) for the groups treated after the disease induction.725 Falk et al.
with PBS solutions of the PLP139–151(C140S) antigens
(Fig. 6). The experiment was carried out in SJL/J mice in
which the disease was induced by the subcutaneous admin-
istration of 50 mg PLP139–151(C140S) peptide in CFA.
The mice were treated either before (days 27 and 23; Fig.
6, left) or after the disease induction (days 3 and 7; Fig. 6,
right). The animals received the intravenous injections of
peptide (top) or 16-mer (bottom) at a dosage of 50 mg, and
control groups received a mock treatment with PBS.
The intravenous treatment with the 16-mer almost com-
pletely prevented the development of the disease (Fig. 6,
bottom). With the treatment before the disease induction
(bottom left), four of the five mice did not show any clini-
cal signs, and only one mouse developed a very mild form
of EAE (score of 1, resulting in a mean score of 0.2). Im-
portantly, the effect of the 16-mer was also evident if the
treatment was done several days after the induction of the
disease (bottom right). Two injections of 50 mg were suffi-
cient to reduce the maximal mean clinical score to a value
of 1.3 compared with a score of 4.5 in the control group.
After the initial attack, which peaked at day 19, most of the
mice returned within 6 d to a condition virtually free of
any clinical symptoms. In contrast to the treatment with
the 16-mer, the effect of the peptide was far less dramatic.
Although peptide treatment before the disease induction
(Fig. 6, top left) resulted at least in some reduction of the
severity of the EAE progression (maximal mean score of
2.2), the treatment after disease induction (top right) re-
sulted in acceleration of disease progression. The onset
shifted by almost 2 d, and a maximal mean score of 5 (i.e.,
100% mortality) was reached earlier, by day 14.
The effect of peptide treatment on enhancing instead of
suppressing the disease progression could not be overcome
by an increase in dosage. Even when 250 mg was adminis-
tered to the animals, no reverse in the trend was apparent
(data not shown). On the other hand, with the 16-mer a
single injection of 50 mg on day 7 was found to be suffi-
cient to produce a strong suppression (Fig. 7, bottom). At
this time point, only very little submeningeal, perivascular
infiltration was evident in brain sections taken from SJL/J
mice immunized with the peptide (data not shown). How-
ever, the effect of the 16-mer was found to be highly spe-
cific, and no suppression was evident if the disease was in-
duced with the PLP178–191 peptide (Fig. 7, top) instead of
the PLP139–151 peptide (Fig. 7, bottom). Similar results
were also obtained with MBP antigens containing the
epitopes MBP86–100 and MBP86–101 (Fig. 8). Only a
relatively modest suppression was observed after an injec-
tion of 100 mg of MBP86–100 16-mer on days 3 and 7
(triangles, top). The effect was greatly enhanced after using
a 16-mer containing the more antigenic epitope MBP86–
101 at an increased dosage (200 mg) on days 8 and 12. Also
in the MBP system, the intravenous treatment with pep-
tides had little or no effect (filled circles).
Figure 7. Specificity of EAE suppression by intravenous injections of
PLP139–151(C140S) 16-mers. SJL/J mice received intravenous injections
of 50 mg PLP139–151(C140S) peptide or PLP139–151(C140S) 16-mer
7 d after the induction of the disease by the subcutaneous injection of 50
mg PLP178–191(C183S) (top) or PLP139–151(C140S) peptide (bottom).
Groups of six mice were used for the experiment. The incidence rates were
determined as 6/6 (peptide) and 6/6 (16-mer) for the groups immunized
with the PLP178–191(C183S) peptide and as 6/6 (peptide) and 4/6 (16-
mer) for the groups immunized with the PLP139–151(C140S) peptide.
Figure 8. Suppression of EAE by intravenous injections of oligomers
containing the MBP86–100 epitope. SJL/J mice were treated with intra-
venous injections of MBP86–100 (top) or MBP86–101 (bottom). EAE
was induced on day 0 by the subcutaneous injection of 100 mg MBP86–
100 or 200 mg MBP86–101 peptide, respectively. The mice were treated
intravenously with peptide, 16-mer, or PBS at the indicated time points
(arrows) and received dosages of 100 mg of the MBP86–100 or 200 mg of
the MBP86–101 antigens. Groups of 5–10 mice were used for the exper-
iment. The incidence rates were determined as 5/6 (control), 6/6 (pep-
tide), and 4/6 (16-mer) for the groups primed and treated with the
MBP86–100 epitope and as 5/5 (control), 9/10 (peptide), and 4/10 (16-
mer) for the groups primed and treated with the MBP86–101 epitope.726 Induction and Suppression of EAE by Epitope Multimers
Ex vivo experiments with primary LN cultures (LNCs)
further indicated that in mice treated with the PLP139–
151(C140S) 16-mer, the specific response against this anti-
gen was either reduced, or, as shown in the top left panel
of Fig. 9 (triangles), completely absent. In contrast, the an-
tigen-specific response of LNCs from peptide-treated mice
(filled circles) was similar to that of the control group (open
circles). This silencing of the T cell response, presumably
due to apoptosis or anergy induction, was found to be anti-
gen specific, since the T cell proliferation triggered by
staphylococcal enterotoxin A or B was unaffected (not
shown). The histological analysis of the tissues taken from
the mice revealed interesting differences in the pathology
between the three groups. In the mock-treated animals
(Fig. 9, top right), the lesions showed prominent demye-
lination (arrowheads) in the presence of an inflammatory in-
filtrate that contained numerous polymorphonuclear cells
(small arrows). In the peptide-treated animals (bottom left),
inflammation and demyelination were also evident and the
lesions contained mostly mononuclear cells. Importantly,
however, in cord tissue from animals tolerized with the 16-
mer no inflammation or demyelination was noted (bottom
right), although a low level of inflammation was still
present in the brains of these animals (data not shown).
Long-Term Effects, Control of Relapse, and Induction with
Spinal Cord. Without the 16-mer treatment, in most cases
the mice did not recover from the initial attack, whereas
with the 16-mer treatment the disease was suppressed for at
least 40 d. Long-term studies revealed that after that period
the mice started to relapse (Fig. 10 A, top). The time frame
between the acute episode and the relapse is consistent
with the appearance of a new wave of autoreactive
PLP139–151-specific T cells from the thymus. Although
during the relapsing phase the T cell response reportedly
becomes more heterogeneous due to epitope spreading
(32–34), an additional intravenous injection with the
PLP139–151(C140S) 16-mer on day 40 was still effective
in further preventing the appearance of clinical symptoms
(Fig. 10 A, bottom). A similar suppression was also
achieved when the disease was triggered by broadly stimu-
lating spinal cord homogenate instead of a single epitope
(Fig. 10 B). Compared with mice induced with the
PLP139–151 peptide, the treatment was slightly less effec-
tive, but a strong suppression was also evident after induc-
tion with spinal cord (Fig. 10 B, top). Previous reports in-
dicated that PLP139–151 is the dominant epitope in SJL/J
mice after immunization with spinal cord homogenate
(35). By using a 16-mer with this immunodominant
epitope the maximal daily mean score of the initial attack
was reduced to only 1.7 compared with 4.5 for the control
group, and a complete recovery of the 16-mer–treated
mice was observed by day 34 before the mice started to re-
lapse. A second dose, administered on day 12, greatly en-
hanced the suppressive effect (Fig. 10 B, bottom). In this
experiment, the mice treated twice with the 16-mer re-
mained free of clinical symptoms for .60 d.
Figure 9. Pathological analy-
sis and lymphocyte proliferative
response after intravenous treat-
ment with PLP139–151(C140S)
16-mer. EAE was induced in
SJL/J mice with PLP139–151
(C140S) peptide. 7 d later, the
mice received intravenous injec-
tions of either 50 mg PLP139–151
(C140S) peptide, PLP139–151
(C140S) 16-mer, or mock injec-
tions of PBS. 7 d later (day 14),
LNs were removed to test the ex
vivo response, and the mice were
perfused with Trump’s fixative
before the removal of the spinal
cord for the histological analysis
of disease. The ex vivo response
of primary LNCs of peptide-,
16-mer–, and mock-treated mice
is shown in the top left panel.
LNCs were challenged in a pro-
liferation assay with titrated
amounts of PLP139–151(C140S)
16-mer (top left). The prolifera-
tion assay was performed essen-
tially as described in the legend
to Fig. 2. The other panels show
the histochemical image of 1-mm-
thick plastic-embedded tissue stained with toluidine blue. The samples derived from the mock-treated control animal (top right) and from the peptide-
treated mouse (bottom left) show submeningeal lesions typical of EAE (meninges located on the left of the panels). The meningeal vessels were inflamed,
and numerous inflammatory cells were detected within the cord parenchyma (arrows). In tissues from control animals, large numbers of polymorphonu-
clear cells were evident (small arrows). Demyelinated axons (arrowheads) were present within the inflamed area of the cord. In contrast, in the sample
derived from the 16-mer–treated mouse (bottom right), the meningeal vessels were not inflamed and the cord parenchyma showed no evidence of in-
flammation or demyelination. Original magnifications: 3500.727 Falk et al.
Discussion
The trimolecular interaction of TCR–peptide–MHC
represents the structural basis of the immune response. Sev-
eral attempts have already been made to modulate this in-
teraction with the intent to enhance the response to a vac-
cine (36–38), and multimerization or oligomerization is
another approach in this direction. Soluble multivalent
peptide–MHC complexes were previously shown to si-
multaneously engage multiple TCRs resulting in com-
plexes, which are significantly more stable than the respec-
tive monomeric complex (39, 40). Furthermore, the TCR
cross-linking promoted by this interaction initiates signal
transduction and triggers the activation cascade of the T
cell, which significantly lowers the threshold for the activa-
tion (41). In addition, the use of multimerized T cell
epitopes can produce similar effects. The multimerized an-
tigens, which were designed to form multivalent arrays of
peptide–MHC complexes on the surface of the APCs, can
show, in some cases, great enhancement in the antigenicity
of the epitope.
The oligomerized encephalitogenic antigens presented in
this study were not only more effective in the stimulation
of antigen-specific T cells in vitro, but also induced stron-
ger primary T cell responses in vivo. The priming of mice
with these antigens resulted in the manifestation of very se-
vere forms of EAE, evident even in resistant strains. Earlier
studies suggested that the failure of resistant B10.S mice to
develop EAE is caused by a paucity of high-affinity auto-
reactive T cells (42, 43). Since the oligomerized antigens were
particularly effective in the stimulation of low-avidity T
cells, the increased encephalitogenicity might be attribut-
able to the induction of a broader T cell response by the re-
cruitment of a larger number of T cell clones. Part of this
might be due to a potentially reduced need for costimula-
tory signals. Studies with tetrameric peptide–MHC com-
Figure 10. Control of relapse and effect of intrave-
nous treatment with PLP139–151(C140S) 16-mer after
EAE induction with spinal cord homogenate. (A)
Long-term effect of the treatment with PLP 16-mer
and prevention of relapse. The top panel shows an ex-
periment in which SJL/J mice received only a single
intravenous dosage of 50 mg PLP139–151 (C140S) 16-
mer on day 7. The clinical score is plotted in compari-
son to the score of a control group treated with PBS
only. In the experiment shown in the bottom panel,
mice either received only the single dosage of 50 mg
16-mer on day 7 or were treated again the same way on
day 40. Groups of four mice were used for the experi-
ments, and the disease was induced by subcutaneous
administration of PLP139–151(C140S) peptide. (B)
Treatment of EAE with PLP139–151(C140S) 16-mer
after induction with spinal cord homogenate. The ex-
periment was carried out as described above except that
4 mg of spinal cord homogenate instead of the PLP
peptide was used for the disease induction. The SJL/J
mice received intravenous injections of 50 mg 16-mer
either on day 8 (top) or on days 8 and 12 (bottom). The
control group was treated with mock injections of PBS.
Groups of five mice were used for this experiment.728 Induction and Suppression of EAE by Epitope Multimers
plexes indicated that at least for these tetramers the influ-
ence of CD4 on the binding is diminished (40). In
addition, the activation of the APCs by MHC cross-linking
(1, 44) and the “proteinization” of the epitope could con-
tribute to the effect. An increased stability of the epitope,
altered routes of antigen presentation, and a more effective
T cell stimulation by an activated APC might be relevant
particularly for the increase in antigenicity in vivo. Another
factor might be the strong enhancement of a Th1-type T
cell response. Autoreactive CD41 T cells of the Th1 type
are the driving force in T cell–mediated autoimmune dis-
eases, and a preferred activation of this T cell subset would
certainly promote the progression of EAE. In fact, a recent
study (45) indicated that the resistance of B10.S mice might
be due to a failure of antigen-specific CD41 T cells to up-
regulate CD40 ligand. This failure abrogates the release of
IL-12 and subsequently affects the expression level of the
b2 subunit of IL-12R, a receptor crucial in controlling
Th1 lineage commitment. At this point, however, it is not
clear whether the enhancement of encephalitogenicity is
actually caused by a selective activation of Th1 T cells.
Maybe even more important than the improved stimula-
tion is the effect of oligomerized antigens if administered
intravenously on the suppression of the autoimmune dis-
ease. High zone tolerance as a mechanism of T cell toler-
ization has been known for some time (13), but its practi-
cality has been limited by the requirement of extremely
high antigen (peptide, protein) levels. The enhanced anti-
genicity of multimerized antigens might make this ap-
proach more feasible. A drastic decrease in incidence and
severity of EAE was achieved after a single intravenous
treatment with a relatively low dosage of 50 mg per mouse.
In vitro experiments with HA306–318 oligomers and hu-
man influenza virus–specific T cells indicated that the un-
derlying mechanism is most likely the apoptotic elimina-
tion of the “overstimulated” autoreactive T cell (data not
shown). The reduction in the antigen-specific ex vivo re-
sponse of mice treated with encephalitogenic oligomers
and the long period of protection after treatment are con-
sistent and suggest that this mechanism is also responsible
for the specific suppression in the EAE system. Impor-
tantly, the suppression was also observed at the onset of the
relapsing phase and after disease induction with spinal cord
homogenate. The effectiveness of the oligomers in these
situations together with the observation that a fraction of
the autoreactive T cell population actually fails to respond
to the multimerized antigen suggests that, in addition to the
antigen-specific suicidal T cell elimination, “bystander” ef-
fects contribute to the high zone suppression.
Thus, oligomerized antigens can be effective in the in-
duction and suppression of the immune response. In addi-
tion to their use as vaccines for the stimulation of preven-
tive pathogen-specific T cell responses, they might be
particularly valuable for the immunotherapy of tumors.
Most chronic autoimmune diseases are mediated by CD41
T cells, and the recruitment of autoreactive CD41 T cells
specific for tumor antigens (46) might permit the develop-
ment of a similar situation, with the immune response di-
rected towards the specific destruction of the transformed
tissue. Furthermore, the striking effects of multimeric T
cell epitopes in high zone applications might provide a new
stimulus for the use of autoantigens in therapies aimed at
the specific suppression of acute or chronic autoimmune
states.
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